Biotech Values

[dewophile]

Interesting note was the low dose group got an RVR rate same as SOC, but it got an EVR rate same as the high doses of IFN-L

that is curious - it must be due to the higher dropout rate on SOC since most who get an RVR who stay on treatment get to EVR

And of course, the best was the AE rates and much much lower rates of dose reduction

i still think this is the most significant piece of the data. with DAAs the added efficacy that lambda brings becomes less important than the tolerability. In fact, with ever improving regimens it may be that one day the only failures we'll see on treatment are those who can't complete the treatment